Meeting
2020 ASCO Virtual Scientific Program
Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.
Authors
Vadryn Pierre
Astrazeneca, Gaithersburg, MD
Vadryn Pierre , Xiang Guo , Ignacio Gonzalez-Garcia , Nassim Morsli , Alejandro Javier Yovine , Weimin Li , Rajesh Narwal , Lorin Roskos , Paul Baverel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT01693562, NCT02319044, NCT02207530, NCT02369874
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6549)
DOI
10.1200/JCO.2020.38.15_suppl.6549
Abstract #
6549
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Xiang Guo
Poster
2019 Gastrointestinal Cancers Symposium
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu
Poster
2015 Gastrointestinal Cancers Symposium
Interleukin-6 (IL-6) as an inflammatory biomarker in patients with hepatobiliary cancers.
First Author: Sidra Anwar
Poster
2014 ASCO Annual Meeting
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.
First Author: Yingmiao Liu